ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 898

Treatment and Outcome of Patients with a Diagnosis of Healed Arteritis on Temporal Artery Biopsy

Daniel Jo1, Melissa Fazzari2, Donald Brand3, Steven E. Carsons4 and Elise Belilos1, 1Rheumatology, Winthrop University Hospital, Mineola, NY, 2Biostatistics, Winthrop University Hospital, Mineola, NY, 3Office of Health Outcomes Research, Winthrop University Hospital, Mineola, NY, 4Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, NY, USA, Mineola, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: giant cell arteritis, steroids and temporal arteritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Temporal artery biopsy (TAB) is the gold standard for the diagnosis of Giant Cell Arteritis (GCA), yet is limited by the presence of skip lesions and atypical pathological features. The entity of “healed arteritis” (HA) has been described in the literature as having focal to complete loss of internal elastic lamina, irregular intimal thickening, medial fibrosis or neovascularization, and usually scant, if any, inflammation.We analyzed the treatment patterns and outcomes in patients with a diagnosis of HA on TAB, compared with positive and negative biopsies in patients suspected of GCA.

Methods: We identified 18 patients with TAB pathology report indicating HA, and matched these to 27 with classically positive biopsies (POS), and 29 with negative biopsies (NEG). Statistical analysis compared corticosteroid (CS) management among these 3 cohorts. Changes in CS dose immediately following TAB report were recorded. The 90 day CS requirements were expressed as area under the curve (AUC). Rheumatologists’ pre-biopsy clinical suspicion for GCA, clinical and laboratory parameters, remission rates, and steroid-related adverse events were also analyzed.

Results: In the immediate post-biopsy follow-up period, HA and POS were both less likely to have dose decreases compared to NEG (p<0.001). However, the mean 90 day cumulative steroid dose AUC was significantly lower in HA versus POS (2663 mg vs 4206 mg; p=0.01), and were similar to NEG (2663 mg vs 2088mg; p=0.34). At long term follow up (mean 3.4 +/- 0.41 years), patients with HA tended to more often be in remission (defined as off steroids or tapering with quiescent disease). Both HA and NEG had fewer adverse effects from CS (29 and 14%, respectively) compared to POS (48%) (p=0.02).  When patients with HA were compared to POS, they were significantly more likely to have a low-moderate (vs. high) pre-biopsy clinical index of suspicion for GCA (p=0.0032). Pre-biopsy duration and cumulative CS dose was similar among all groups, as was frequency of polymyalgia rheumatica (PMR). Mean erythrocyte sedimentation rate was significantly higher in the POS group compared to the HA and NEG groups (87 vs. 54 and 66 mm/hr, p=0.023 and 0.01 respectively), while not statistically different between the HA and NEG groups (p=0.32).

Conclusion: Although a report of HA on TAB did not result in immediate reductions in CS, our study shows that ultimately a lower 90 day cumulative dose of CS was utilized in HA. Our data suggests that patients with “healed arteritis” on pathology required less steroid and may be more aggressively tapered without adverse consequence.


Disclosure: D. Jo, None; M. Fazzari, None; D. Brand, None; S. E. Carsons, None; E. Belilos, None.

To cite this abstract in AMA style:

Jo D, Fazzari M, Brand D, Carsons SE, Belilos E. Treatment and Outcome of Patients with a Diagnosis of Healed Arteritis on Temporal Artery Biopsy [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/treatment-and-outcome-of-patients-with-a-diagnosis-of-healed-arteritis-on-temporal-artery-biopsy/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-and-outcome-of-patients-with-a-diagnosis-of-healed-arteritis-on-temporal-artery-biopsy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology